• Margin guidance: Zydus expects to sustain 24% plus EBITDA margins net of foreign exchange in FY27, supported by a resilient $300 million plus US base business and growth across domestic and international operations.
• Mirabegron outlook: Following a settlement, the company maintained strong market share in the fourth quarter and has factored in anticipated price erosion resulting from a three-player competitive market.
• Differentiated pipeline: R&D spending is positioned at approximately 8% of revenue, with key India molecule Saroglitazar surpassing 500 crore and poised to scale beyond 1,000 crore.
• Assertio commercial synergies: Integrating Assertio and the Rolvedon asset into the existing US oncology specialty task force is projected to yield cost synergies and be earnings-accretive in the first year without margin dilution.
• Semaglutide global expansion: Having achieved the number two position in India's branded generic injectable market as of April, the company plans to launch its novel formulation in 20-plus international markets over the next 12 to 24 months.